|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7805 News |
|
| «12...122123124125126127128129130131132...156157» |
- Trial completion: ECHO-DIAB: Alteration of Myocardial Deformations in Diabetes: Relationship to Micro-angiopathy (clinicaltrials.gov) - Apr 17, 2013
P=N/A, N=61, Completed, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed
- Trial withdrawal: Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA) (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=0, Withdrawn, Sponsor: Northwestern University
Recruiting --> Completed Recruiting --> Withdrawn
- Enrollment change: Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA) (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=0, Withdrawn, Sponsor: Northwestern University
Recruiting --> Withdrawn N=32 --> 0
- Synera (lidocaine 70 mg/tetracaine 70 mg/heated Topical Patch) / Miravo, Eurocept, Galen, Samaritan Pharma
Enrollment open: OUCH: Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications (clinicaltrials.gov) - Apr 15, 2013
P4, N=30, Recruiting, Sponsor: Brown, Theodore R., M.D., MPH
N=32 --> 0 Not yet recruiting --> Recruiting
- Enrollment change, IO biomarker: Neuro-SGSp: Neurotrophins Implications in Primary Sj (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=40, Completed, Sponsor: University Hospital, Limoges
Not yet recruiting --> Recruiting N=80 --> 40
- | New P4 trial: The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial (clinicaltrials.gov) - Apr 15, 2013
P4, N=70, Recruiting, Sponsor: University of Manitoba
- Trial completion, IO biomarker: Neuro-SGSp: Neurotrophins Implications in Primary Sj (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=40, Completed, Sponsor: University Hospital, Limoges
N=80 --> 40 Recruiting --> Completed
- Enrollment change: Performance Study to Test the GlucoMen (clinicaltrials.gov) - Apr 14, 2013
P=N/A, N=12, Completed, Sponsor: Medical University of Graz
Recruiting --> Completed N=20 --> 12
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open: A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov) - Apr 14, 2013
P=N/A, N=100, Recruiting, Sponsor: Hoffmann-La Roche
N=20 --> 12 Not yet recruiting --> Recruiting
- Enrollment open: Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). (clinicaltrials.gov) - Apr 14, 2013
P1, N=30, Recruiting, Sponsor: GE Healthcare
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Trial completion: Performance Study to Test the GlucoMen (clinicaltrials.gov) - Apr 14, 2013
P=N/A, N=12, Completed, Sponsor: Medical University of Graz
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- |||| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Trial completion: BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes (clinicaltrials.gov) - Apr 14, 2013
P2, N=70, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Completed Recruiting --> Completed
- ELND 002 / Perrigo Company
Trial termination: A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Apr 11, 2013
P1, N=32, Terminated, Sponsor: Elan Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Terminated
- ELND 002 / Perrigo Company
Enrollment change: A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Apr 11, 2013
P1, N=32, Terminated, Sponsor: Elan Pharmaceuticals
Active, not recruiting --> Terminated N=100 --> 32
- ELND 002 / Perrigo Company
Trial termination: A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Apr 11, 2013
P1, N=12, Terminated, Sponsor: Elan Pharmaceuticals
N=100 --> 32 Active, not recruiting --> Terminated
- ELND 002 / Perrigo Company
Enrollment change: A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Apr 11, 2013
P1, N=12, Terminated, Sponsor: Elan Pharmaceuticals
Active, not recruiting --> Terminated N=80 --> 12
- ||| decernotinib (VX-509) / Vertex
New P2/3 trial: A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Apr 10, 2013
P2/3, N=40, Recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
- Trial withdrawal: Non-enhanced Magnetic Resonance Angiography of Diabetic Ischemic Lower Limbs (clinicaltrials.gov) - Apr 10, 2013
P=N/A, N=0, Withdrawn, Sponsor: Aarhus University Hospital
N=80 --> 12 Not yet recruiting --> Withdrawn
- mocravimod (KRP-203) / Priothera
Trial termination: Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Apr 10, 2013
P2, N=22, Terminated, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Withdrawn Recruiting --> Terminated
- Enrollment change: Non-enhanced Magnetic Resonance Angiography of Diabetic Ischemic Lower Limbs (clinicaltrials.gov) - Apr 10, 2013
P=N/A, N=0, Withdrawn, Sponsor: Aarhus University Hospital
Recruiting --> Terminated N=50 --> 0
- Clinical: FFF: Pilot Study of Free From Falls Program in Multiple Sclerosis (clinicaltrials.gov) - Apr 9, 2013
P=N/A, N=36, Recruiting, Sponsor: Oregon Health and Science University
- |||||| Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Enrollment open: Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia (clinicaltrials.gov) - Apr 9, 2013
P3, N=95, Recruiting, Sponsor: Octapharma
N=50 --> 0 Not yet recruiting --> Recruiting
- Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Clinical: SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) - Apr 8, 2013
P=N/A, N=10, Recruiting, Sponsor: St. Louis University
- New P2 trial: Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes (clinicaltrials.gov) - Apr 8, 2013
P2, N=0, Withdrawn, Sponsor: Institut de Recherches Cliniques de Montreal
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
New P1/2 trial: DILT1D: Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2 (clinicaltrials.gov) - Apr 8, 2013
P1/2, N=40, Recruiting, Sponsor: Cambridge University Hospitals NHS Foundation Trust
- Enrollment closed, IO biomarker: Autoimmune Thyroid Disease Genetic Study (clinicaltrials.gov) - Apr 8, 2013
P=N/A, N=4000, Active, not recruiting, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice (clinicaltrials.gov) - Apr 7, 2013
P=N/A, N=4208, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Enrolling by invitation --> Active, not recruiting Recruiting --> Completed
- Trial completion: Effects of Vaporized Marijuana on Neuropathic Pain (clinicaltrials.gov) - Apr 4, 2013
P1/2, N=44, Completed, Sponsor: University of California, Davis
Recruiting --> Completed Active, not recruiting --> Completed
- Macugen (pegaptanib) / Bausch Health
Enrollment change, Monotherapy: Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen (clinicaltrials.gov) - Apr 4, 2013
P2, N=22, Completed, Sponsor: Association for Innovation and Biomedical Research on Light and Image
Active, not recruiting --> Completed N=30 --> 22
- || prezalumab (AMG 557) / Amgen, AstraZeneca
Enrollment change: A Study of AMG 557 in Adults With Systemic Lupus Erythematosus (clinicaltrials.gov) - Apr 4, 2013
P1, N=58, Completed, Sponsor: Amgen
N=30 --> 22 N=48 --> 58
- Macugen (pegaptanib) / Bausch Health
Trial completion, Monotherapy: Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen (clinicaltrials.gov) - Apr 4, 2013
P2, N=22, Completed, Sponsor: Association for Innovation and Biomedical Research on Light and Image
N=48 --> 58 Active, not recruiting --> Completed
- ||| prezalumab (AMG 557) / Amgen, AstraZeneca
Trial completion: A Study of AMG 557 in Adults With Systemic Lupus Erythematosus (clinicaltrials.gov) - Apr 4, 2013
P1, N=58, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Completed
- || Trial initiation date, Compliance, Patient reported outcomes: Impact Of RA Therapy Compliance On Patient-Reported Outcomes (clinicaltrials.gov) - Apr 3, 2013
P=N/A, N=396, Completed, Sponsor: Pfizer
Recruiting --> Completed Initiation date: Oct 2011 --> Feb 2012
- || Enrollment change, Compliance, Patient reported outcomes: Impact Of RA Therapy Compliance On Patient-Reported Outcomes (clinicaltrials.gov) - Apr 3, 2013
P=N/A, N=396, Completed, Sponsor: Pfizer
Initiation date: Oct 2011 --> Feb 2012 N=600 --> 396
- Enrollment change: TIME: Timing of Insulin Before Meals Everyday (clinicaltrials.gov) - Apr 3, 2013
P=N/A, N=40, Completed, Sponsor: University of New Mexico
N=600 --> 396 N=80 --> 40
- | New P4 trial: Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study (clinicaltrials.gov) - Apr 3, 2013
P4, N=100, Active, not recruiting, Sponsor: University of Colorado Denver School of Medicine Barbara Davis Center
- Trial completion: TIME: Timing of Insulin Before Meals Everyday (clinicaltrials.gov) - Apr 3, 2013
P=N/A, N=40, Completed, Sponsor: University of New Mexico
N=80 --> 40 Active, not recruiting --> Completed
- ||||| insulin peglispro (LY2605541) / Eli Lilly
Trial initiation date: A Study in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Apr 2, 2013
P3, N=450, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Initiation date: Aug 2011 --> Jan 2012
- Clinical: DP3: Tissue-Specific Metabolic Reprogramming in Diabetic Complications (clinicaltrials.gov) - Apr 2, 2013
P=N/A, N=40, Recruiting, Sponsor: University of Michigan
- ||| Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
New P3 trial: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. (clinicaltrials.gov) - Apr 2, 2013
P3, N=48, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
- | New P2 trial: PSO4: Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children (clinicaltrials.gov) - Apr 2, 2013
P2, N=120, Recruiting, Sponsor: In Home Closed Loop Study Group
- ||| rHIgM22 / Acorda
Enrollment open: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis (clinicaltrials.gov) - Apr 2, 2013
P1, N=71, Recruiting, Sponsor: Acorda Therapeutics
Initiation date: Aug 2011 --> Jan 2012 Not yet recruiting --> Recruiting
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients (clinicaltrials.gov) - Apr 2, 2013
P3, N=72, Completed, Sponsor: Chugai Pharma Taiwan
Not yet recruiting --> Recruiting Recruiting --> Completed
- Januvia (sitagliptin) / Merck (MSD)
Trial completion: Effects of Sitagliptin (Januvia (clinicaltrials.gov) - Apr 2, 2013
P=N/A, N=140, Completed, Sponsor: University of Colorado Denver School of Medicine Barbara Davis Center
Recruiting --> Completed Active, not recruiting --> Completed
- | Orencia (abatacept) / BMS
Trial completion: Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg (clinicaltrials.gov) - Apr 2, 2013
P1, N=13, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- glatiramer acetate / Generic mfg.
Enrollment change: Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities (clinicaltrials.gov) - Apr 1, 2013
P4, N=10, Completed, Sponsor: University of Southern California
Active, not recruiting --> Completed N=18 --> 10
- Synera (lidocaine 70 mg/tetracaine 70 mg/heated Topical Patch) / Miravo, Eurocept, Galen, Samaritan Pharma
New P4 trial: OUCH: Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications (clinicaltrials.gov) - Apr 1, 2013
P4, N=30, Recruiting, Sponsor: Brown, Theodore R., M.D., MPH
- glatiramer acetate / Generic mfg.
Trial completion: Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities (clinicaltrials.gov) - Apr 1, 2013
P4, N=10, Completed, Sponsor: University of Southern California
N=18 --> 10 Recruiting --> Completed
- Trial completion: Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells (clinicaltrials.gov) - Apr 1, 2013
P1, N=56, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed Recruiting --> Completed
- ||| Xeljanz (tofacitinib) / Pfizer
Clinical: A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Apr 1, 2013
P1, N=148, Completed, Sponsor: Pfizer
Recruiting --> Completed Active, not recruiting --> Completed